significantTreatment update
Pirtobrutinib shows activity in covalent BTK inhibitor-pretreated WM
Waldenström's Macroglobulinemia →Summary
Non-covalent (reversible) BTK inhibitor pirtobrutinib demonstrated meaningful activity in WM patients previously treated with covalent BTK inhibitors. The BRUIN trial established pirtobrutinib as a viable option after ibrutinib or zanubrutinib failure. Pirtobrutinib + venetoclax combination reported a 56% VGPR rate in early data, suggesting deep responses with combination approaches.
Related treatments
ZanubrutinibSecond-generation selective BTK inhibitor
1st line~95% ORR; 36% VGPR+CR
IbrutinibFirst-generation BTK inhibitor
1st line90% ORR; 73% MRR (previously treated)
VenetoclaxBCL2 inhibitor
2nd line~70% MRR (relapsed/refractory)
PirtobrutinibNon-covalent (reversible) BTK inhibitor
2nd line~68% ORR (after covalent BTKi); 56% VGPR with venetoclax combo
More from Waldenström's Macroglobulinemia
incrementalTreatment update
Emerging CAR-T and bispecific antibody approaches for WM
incrementalNew research
BTK degraders (PROTACs) enter clinical trials for B-cell malignancies
incrementalNew research
Genomics-guided treatment selection advances in WM
significantTreatment update
Ibrutinib + venetoclax fixed-duration combination in treatment-naive WM
ID: waldenstroms-macroglobulinemia-update-1Type: treatment_updateImpact: significant